RNA-targeting strategy successfully blocks a vexing driver of Parkinson's disease A new drug-like compound prevents the body from producing a protein thats often at the root of Parkinsons.
December 30, 2020
JUPITER, FLA Scientists at Scripps Research have developed a drug-like compound that selectively prevents production of the protein underlying most causes of Parkinson's disease, alpha-synuclein.
The study underscores the untapped potential of addressing diseases mediated by undruggable proteins via the messenger RNAs that encode them.
To be published the week of Dec. 30 in the Proceedings of the National Academies of Sciences, the study is authored by Scripps Research chemistry professor Matthew D. Disney, PhD, and graduate student Peiyuan Zhang, and their colleagues.
If DNA serves as the code of life, genes within DNA provide the code for specific proteins. For a gene to actually encode a protein, however, it must first be transcribed with the help of messenger RNA. The messenger RNA serves as a template for protein production, a process called translation, which is orchestrated by molecular machines called ribosomes.
Disney's alpha-synuclein compound, which he named synucleozid, stops the ribosome from detecting the messenger RNA template, thus preventing the translation or printing of the alpha-synuclein protein. The Scripps Research team collaborated on the study with a team from Rutgers University led by M. Maral Mouradian, MD, director of the Institute for Neurological Therapeutics.
We showed not only that we can inhibit the translation of alpha-synuclein, which is an important protein in Parkinson's disease and dementia, but also that this compound can stop its messenger RNA from being recognized by a ribosome, Disney says. In other words, the compound doesn't allow the messenger RNA to be made into the alpha-synuclein protein. We believe this unique mechanism is broadly applicable.
Disney has spent more than a decade building technologies capable of identifying drug-like compounds to do this. A system he invented called Inforna computationally uses genetic sequence to predict complementary small molecule-RNA interactions.
Most drugs on the market work by binding to problematic proteins to limit their ability to cause harm. However, for a drug to bind, those proteins must have stable structures with favorable binding pockets.
The alpha-synuclein protein is one example of many in the genome that have confounded scientists' efforts to bind with medications, due to their undefined structure.
In fact, the so-called druggable genome is currently comprised of only about 3,000 genes out of an estimated 20,000 protein-coding genes. Disney says his research suggests that many undruggable proteins are transcribed by RNA that do have stable structures, meaning the RNA should be druggable, offering an effective workaround.
We are applying this across a number of disease indications, with our priority being applying these approaches to the diseases that have the most urgent medical need, Disney says.
Parkinson's disease is clearly among them. With an estimated 1 million people in the United States alone living with the condition, at an estimated cost of over $50 billion annually, Parkinson's causes chronic, progressive disability due to the death of dopamine-producing cells in the brain. The symptoms may include slowness of movements, impaired coordination, limb and trunk stiffness, tremor, and eventually dementia and psychiatric manifestations.
Symptoms emerge as the alpha-synuclein protein accumulates in brain cells, misfolding and aggregating to form clumps called Lewy bodies and Lewy neurites. Certain forms of these aggregates are toxic and eventually lead to the cell's death.
Mouradian says down-regulating production of alpha-synuclein may have therapeutic promise.
The precise molecular mechanisms driving Parkinson's disease remain to be fully elucidated. However, the amount of alpha-synuclein protein levels is an important factor in its pathologic misfolding and aggregation, initiating a cascade of events that lead to neuronal damage and Parkinson's symptoms, Mouradian says. Therefore, it stands to reason that reducing the amount of alpha-synuclein protein can mitigate this disease-causing cascade, and slow down or stop disease progression. Identification of this alpha-synuclein messenger RNA-targeting probe will enable us to evaluate the therapeutic value of reducing alpha-synuclein production in patients.
Many people with Parkinson's respond for a time to therapeutics that include dopamine replacement. But adding back dopamine doesn't protect the nervous system from the progressively worsening disease process, and introduces its own set of sometimes serious side-effects.
We wanted to see if we could inhibit this protein from even being made by targeting the messenger RNA that encodes it, Disney says.
The benefit of choosing a small molecule to do this rather than an RNA-binding oligonucleotide is that a therapeutic agent must be very, very small to cross the blood-brain barrier. It must also be selective, and apparently these starting compounds are selective.
We found the molecule was very selective at the RNA level. We also studied the effects at the protein level, and the molecule was also selective on that level, Disney says.
But Disney notes that this is a proof-of-concept study, and that a long road lies ahead before Synucleozid might become a Parkinson's drug candidate that can move into clinical trials in humans.
We are just at the beginning here, and there is much work to do Disney says. We are showing that if you can inhibit a protein from being made, that may be advantageous over waiting to address its role in disease until after it is already made.
The study, Trans
Most recent headlines
01/01/2026
Latin Grammy Cultural Foundation Announces 2026 Noel Schajris Scholarship The scholarship will cover tuition and housing for one Berklee College of Music stud...
01/01/2026
New year, new games, all with RTX 5080-powered cloud energy. GeForce NOW is kicking off 2026 by looking back at an unforgettable year of wins and wildly high fr...
31/12/2025
Back to All News
NFL Christmas Gameday on Netflix Scores Again With the Lions-V...
30/12/2025
As the College Football Playoff Enters the Quarterfinals, ESPN Blows Out Its Meg...
30/12/2025
SVG's Best of 2025: Original ArticlesTake a look back at all our coverage of big-time productions, game-changing technologies, and state-of-the-art new faci...
30/12/2025
MELBOURNE, Fla., Dec. 30, 2025 - L3Harris Technologies (NYSE: LHX) will release its fourth quarter 2025 financial results before the market opens on Thursday, J...
30/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
30/12/2025
It marked the first civilian operational authorization for a HAPS flight in Europe, led by Space42's subsidiary, Mira Aerospace
The flight demonstrated HAP...
29/12/2025
San Francisco 49ers Strike Gold With Halftime Laser SpectacularStunning display caps $200 million renovation of Levi's Stadium techBy Dan Daley, Audio Edito...
29/12/2025
The Cup's Around the Corner: An Inside Look at Broadcast Preparations for th...
29/12/2025
SVG's Best of 2025: Longform VideoWatch the standout keynote conversations, deep dives, and panel discussions from the year for free on SVG PLAY!By Brandon ...
29/12/2025
From crisper Lossless audio and immersive music videos in beta to new Audiobooks+ plans, custom transitions between tracks, and in-app Messages, we keep levelin...
29/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
27/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
26/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
26/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
25/12/2025
Holiday lights are twinkling, hot cocoa's on the stove and gamers are settling in for a well-earned break.
Whether staying in or heading on a winter getawa...
24/12/2025
What is AI good for? Posted by MTI Film on December 24, 2025
What is AI good for?
What is AI good for?
It's been three years since ChatGPT first cap...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Back to All News
The Boyfriend' Season 2 Unveils Heartwarming Trailer, Key...
24/12/2025
Back to All News
Love, Fights, and Everything in Between: Badly in Love' Returns for Season 2
Entertainment
24 December 2025
GlobalJapan
Link copied t...
24/12/2025
Scripps Research study links sleep variability with sleep apnea and hypertension How consumers' digital activity trackers could enable personalized health s...
23/12/2025
How guilas Cibae as Dominican Winter League Games Are Locally Produced for Glob...
23/12/2025
BitFire's Jim Akimchuk on Supplying Scalability and Customization in the Clo...
23/12/2025
CAMB.AI Enables European Athletics to Offer Multi-Language SupportPlan is to eventually offer translation into all languages spoken in EuropeBy Ken Kerschbaumer...
23/12/2025
Analysis: As sports media values trend negative, scarcity and quality are king By Callum McCarthy, Editor-at-Large
Monday, December 22, 2025 - 14:08
Print ...
23/12/2025
ESPN, Disney, and NBA Return to the Animated Altcast Fray With Second Edition of...
23/12/2025
End the Year on a High Note and Donate to the Sports Broadcasting Fund Today!By Ken Kerschbaumer, Editorial Director
Tuesday, December 23, 2025 - 12:25 pm
P...
23/12/2025
The year is winding down, the weather outside is frightful, and it's the perfect time to escape into a story that warms the heart. For listeners looking for...
23/12/2025
A Zeus motor is hot fire tested at L3Harris' Camden, Arkansas, solid rocket ...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Lightware will exhibit several major product innovations at ISE 2026, including the new USB-C BOOSTER-V1, Google Meet. integration for various Taurus UCX models...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Taking the Stage at Carnegie Hall-On a Global Scale Boston Conservatory Orchestra students reflect on their epic concert marking the 80th session of the UN Gene...
23/12/2025
Back to All News
Netflix's The Great Flood and Culinary Class Wars 2 Top Gl...
23/12/2025
Back to All News
Stranger Things By the Numbers: How the Global Phenomenon Shap...
23/12/2025
Experience the power of WO Automation for Radio's newest service, the System Effectiveness Review. Designed to help you achieve more, a System Effectiveness...
23/12/2025
23 Dec 2025
VEON's Beeline Kazakhstan and Rakuten Symphony Collaborate to A...
23/12/2025
Back to All News
How Steamy Can It Get? Single's Inferno' Season 5 Pre...
23/12/2025
Back to All News
33 Million Global Viewers on Netflix Watched Jake Paul vs. Ant...
RNA-targeting strategy successfully blocks a vexing driver of Parkinson's disease A new drug-like compound prevents the body from producing a protein thats often at the root of Parkinsons.
